Please assess the completion status of the following clinical trial:

Trial Title: A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetics currently receiving a stable dose of TZD monotherapy (pioglitazone 30mg or 45mg, or rosiglitazone 4mg or 8mg) for at least 12 weeks prior to screening.~* Hemoglobin A1c (HbA1c) \> = 7.0% and \< = 10.5%~* Body mass index \< = 45kg/m2~* Fasting C-peptide \> = 1 ng/mL~Exclusion Criteria:~* Symptomatic poorly controlled diabetes~* Recent cardiac or cerebrovascular event~* Serum creatinine \> = 2.0 mg/dL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin plus open-label TZD (A) (Type: EXPERIMENTAL): Saxagliptin PLUS pioglitazone OR rosiglitazone~PLUS open-label metformin (as needed as rescue medication)
- Saxagliptin plus open-label TZD (B) (Type: EXPERIMENTAL): Saxagliptin PLUS pioglitazone OR rosiglitazone~PLUS open-label metformin (as needed as rescue medication)
- Placebo plus open-label TZD (C) (Type: PLACEBO_COMPARATOR): Placebo PLUS pioglitazone OR rosiglitazone~PLUS open-label metformin (as needed as rescue medication)

Based on this trial design, predict the completion outcome and termination type (if applicable).